YU20199A - Heterociklični sukcinimidi i njihova primena kao metaloproteinaznih inhibitora - Google Patents

Heterociklični sukcinimidi i njihova primena kao metaloproteinaznih inhibitora

Info

Publication number
YU20199A
YU20199A YU20199A YU20199A YU20199A YU 20199 A YU20199 A YU 20199A YU 20199 A YU20199 A YU 20199A YU 20199 A YU20199 A YU 20199A YU 20199 A YU20199 A YU 20199A
Authority
YU
Yugoslavia
Prior art keywords
succinamides
heteroaryl
metalloproteinase inhibitors
metalloproteinase
compounds
Prior art date
Application number
YU20199A
Other languages
English (en)
Inventor
Steven L. Bender
Arlindo L. Castelhano
Wesley K.M. Chong
Melwyn A. Abreo
Roland J. Billedeau
Jian Jeffrey Chen
Judith G. Deal
Original Assignee
Agouron Pharmaceuticals Inc.
Syntex (U.S.A.) Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals Inc., Syntex (U.S.A.) Inc. filed Critical Agouron Pharmaceuticals Inc.
Publication of YU20199A publication Critical patent/YU20199A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Predmetni pronalazak je usmeren na jedinjenje formule I, gde R1, R2, R3, R4, R5, X, Y i la su kao što je definisano ovde. Ova jedinjenja su primenljiva za inhibiranje metaloproteinazne aktivnosti pomoću kontaktiranja metaloproteinaze sa efrikasnom količinom jedinjenja pronalaska.[The present invention is directed to compound of formula (I), wherein R1, R2, R3, R4, R5, X, Y and (la) are as defined herein. These compounds are useful for inhibiting the activity of a metalloproteinase by contacting the metalloproteinase with an effective amount of the inventive compounds.
YU20199A 1996-10-24 1997-10-06 Heterociklični sukcinimidi i njihova primena kao metaloproteinaznih inhibitora YU20199A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2911596P 1996-10-24 1996-10-24
US08/823,962 US6008243A (en) 1996-10-24 1997-03-25 Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use

Publications (1)

Publication Number Publication Date
YU20199A true YU20199A (sh) 2001-09-28

Family

ID=26704557

Family Applications (1)

Application Number Title Priority Date Filing Date
YU20199A YU20199A (sh) 1996-10-24 1997-10-06 Heterociklični sukcinimidi i njihova primena kao metaloproteinaznih inhibitora

Country Status (25)

Country Link
US (1) US6008243A (sh)
EP (1) EP0937042A1 (sh)
JP (1) JP2000511201A (sh)
KR (1) KR20000052779A (sh)
CN (1) CN1233237A (sh)
AP (1) AP1360A (sh)
AR (1) AR009124A1 (sh)
AU (1) AU735194C (sh)
BG (1) BG64506B1 (sh)
BR (1) BR9713278A (sh)
CA (1) CA2267879C (sh)
CZ (1) CZ132199A3 (sh)
EA (1) EA003127B1 (sh)
EE (1) EE9900171A (sh)
GE (1) GEP20012578B (sh)
IL (1) IL128914A (sh)
IS (1) IS5000A (sh)
NO (1) NO313281B1 (sh)
NZ (1) NZ334886A (sh)
OA (1) OA11035A (sh)
PL (1) PL332947A1 (sh)
SK (1) SK48499A3 (sh)
TR (2) TR199900874T2 (sh)
WO (1) WO1998017643A1 (sh)
YU (1) YU20199A (sh)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576664B1 (en) * 1997-08-18 2003-06-10 Bristol-Myers Squibb Pharma Company Inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
AU736026B2 (en) * 1997-12-17 2001-07-26 Merck & Co., Inc. Integrin receptor antagonists
JP2002503649A (ja) * 1998-02-13 2002-02-05 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド 細胞増殖抑制剤
US6172064B1 (en) 1998-08-26 2001-01-09 Glaxo Wellcome Inc. Formamides as therapeutic agents
US6329400B1 (en) 1998-08-26 2001-12-11 Glaxo Wellcome Inc. Formamide compounds as therapeutic agents
GB9818605D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Formamide compounds as therepeutic agents
US6934639B1 (en) * 2000-02-25 2005-08-23 Wyeth Methods for designing agents that interact with MMP-13
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
DOP2002000328A (es) * 2001-02-14 2003-08-30 Warner Lambert Co Pirimidinas inhibidoras de metaloproteinasas de matriz
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
MXPA01013326A (es) 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
DOP2002000332A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
MXPA01013171A (es) 2001-02-14 2004-05-21 Warner Lambert Co Inhibidores triciclicos de sulfonamida de metaloproteinasa de matriz.
PA8539401A1 (es) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
MXPA01013172A (es) 2001-02-14 2002-08-21 Warner Lambert Co Inhibidores sulfonamida de metaloproteinasa de matriz.
US6924276B2 (en) * 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
EP1434585A1 (en) 2001-10-12 2004-07-07 Warner-Lambert Company LLC Alkyne matrix metalloproteinase inhibitors
US6962922B2 (en) * 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6667330B2 (en) * 2002-01-31 2003-12-23 Galileo Pharmaceuticals, Inc. Furanone derivatives
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US6894057B2 (en) * 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
AU2003281167A1 (en) * 2002-07-17 2004-02-02 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
CA2492387A1 (en) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric carboxylic of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
WO2004006914A1 (en) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
AU2003281168A1 (en) * 2002-07-17 2004-02-02 Warner-Lambert Company Llc Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
AU2003250470A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
WO2004014375A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
AU2003253186A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004014384A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2004014377A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors
EP1394159A1 (fr) * 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
AU2003250471A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
AU2003249477A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
JP2006501215A (ja) * 2002-08-13 2006-01-12 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としての単環式誘導体
WO2004014378A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
AU2003253150A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
BR0313724A (pt) * 2002-08-13 2005-06-28 Warner Lambert Co Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
US20060247231A1 (en) * 2003-12-18 2006-11-02 Warner-Lambert Company Llc Amide and ester matrix metalloproteinase inhibitors
US7884079B2 (en) * 2004-12-27 2011-02-08 Miller Landon C G 4-aminopyridine and a pharmaceutical composition for treatment of neuronal disorders
US8691835B2 (en) * 2004-12-27 2014-04-08 Landon C. G. Miller 4 aminopyridine and a pharmaceutical composition for treatment of neuronal disorders
CN101796031A (zh) * 2007-06-05 2010-08-04 辉瑞大药厂 杂双环甲酰胺衍生物和它们的药物用途和组合物
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2719690A4 (en) * 2011-04-28 2014-12-31 Japan Tobacco Inc AMIDE COMPOUND AND USE THEREOF IN PHARMACY
WO2015107139A1 (en) 2014-01-17 2015-07-23 Proyecto De Biomedicina Cima, S.L. Compounds for use as antifibrinolytic agents
CN104926707B (zh) * 2015-05-12 2017-10-27 江苏福瑞生物医药有限公司 一种药物中间体的合成方法
CN106749128A (zh) * 2017-01-13 2017-05-31 滕州市悟通香料有限责任公司 一种制备2‑甲基‑3‑巯基呋喃的方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032639A (en) * 1976-03-22 1977-06-28 American Home Products Corporation 2,3,4,4A-Tetrahydro-1H-pyrazino[1,2-a,]quinoxalin-5(6H)-ones and derivatives thereof for relieving hypertension
ZW23187A1 (en) * 1986-12-15 1988-06-29 Hoffmann La Roche Phosphinic acid derivatives
GB9000846D0 (en) * 1990-01-15 1990-03-14 Beecham Group Plc Novel compounds
GB9022117D0 (en) * 1990-10-11 1990-11-21 Beecham Group Plc Novel compounds
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5239078A (en) * 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
DE69108363T2 (de) * 1990-12-03 1995-08-31 Celltech Ltd Peptidylderivate.
EP0586537A4 (en) * 1991-05-28 1997-06-25 Merck & Co Inc Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents
US5256657A (en) * 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5376664A (en) * 1992-07-27 1994-12-27 The Du Pont Merck Pharmaceutical Company Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agents
AU679474B2 (en) * 1992-11-25 1997-07-03 Merck & Co., Inc. Carboxy-peptidyl derivatives as antidegenerative active agents
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
GB9307956D0 (en) * 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
JPH08500124A (ja) * 1993-04-27 1996-01-09 セルテック セラピューティックス リミテッド メタロプロテイナーゼインヒビターとしてのペプチジル誘導体
BR9407217A (pt) * 1993-08-05 1996-09-17 Syntex Inc Inibidores de metaloprotease de matriz
US6013792A (en) * 1993-08-05 2000-01-11 Syntex (U.S.A.), Inc. Matrix metalloprotease inhibitors
UA48121C2 (uk) * 1993-11-04 2002-08-15 Сінтекс (С.Ш.А.) Інк. Інгібітори матричних металопротеаз і фармацетична композиція на їх основі
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
CA2181709A1 (en) * 1994-01-22 1995-07-27 Raymond Paul Beckett Hydroxamic acid derivatives as metalloproteinase inhibitors
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
JPH10500986A (ja) * 1994-05-28 1998-01-27 ブリテッシュ バイオテック ファーマシューティカルズ リミテッド 金属タンパク質分解酵素阻害剤
CA2193691A1 (en) * 1994-06-22 1995-12-28 Andrew Miller Metalloproteinase inhibitors
GB9416897D0 (en) * 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DE69519751T2 (de) * 1995-04-20 2001-04-19 Pfizer Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf
KR980009238A (ko) * 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
DK0757984T3 (da) * 1995-08-08 2003-03-03 Ono Pharmaceutical Co Hydroxamsyrederivater, der kan anvendes til inhibering af gelatinase
DK0861236T4 (da) * 1995-11-13 2006-12-18 Sanofi Aventis Deutschland Cykliske og heterocykliske N-substituerede alphaiminohydroxam- og carboxylsyrer
DE19542189A1 (de) * 1995-11-13 1997-05-15 Hoechst Ag Cyclische N-substituierte alpha-Iminohydroxamsäuren
US5977141A (en) * 1995-11-17 1999-11-02 Warner-Lambert Company Sulfonamide inhibitors of matrix metalloproteinases
DK0874830T3 (da) * 1995-12-08 2003-04-22 Agouron Pharma Metalloproteinaseinhibitor, farmaceutisk præparat indeholdende denne og den farmaceutiske anvendelse samt en fremgangsmåde til fremstilling deraf
TW453995B (en) * 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
ATE214368T1 (de) * 1995-12-22 2002-03-15 Warner Lambert Co Aromatische keto-säure und ihre derivate als inhibitoren der matrix metalloproteinase
US5837224A (en) * 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin
IL125378A0 (en) * 1996-01-23 1999-03-12 Shionogi & Co Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
SK21499A3 (en) * 1996-08-23 2000-05-16 Pfizer Arylsulfonylamino hydroxamic acid derivatives
IL128666A (en) * 1996-08-28 2005-09-25 Procter & Gamble Substituted cyclic amine metalloprotease inhibitors
SK25699A3 (en) * 1996-08-28 1999-10-08 Procter & Gamble 1,4-heterocyclic metallprotease inhibitors

Also Published As

Publication number Publication date
IL128914A (en) 2003-04-10
AU4806097A (en) 1998-05-15
AU735194C (en) 2002-08-08
OA11035A (en) 2002-03-06
NO313281B1 (no) 2002-09-09
JP2000511201A (ja) 2000-08-29
AR009124A1 (es) 2000-03-08
EE9900171A (et) 1999-12-15
CA2267879C (en) 2006-03-14
WO1998017643A1 (en) 1998-04-30
EP0937042A1 (en) 1999-08-25
KR20000052779A (ko) 2000-08-25
NO991922L (no) 1999-04-22
BR9713278A (pt) 1999-11-03
CA2267879A1 (en) 1998-04-30
NO991922D0 (no) 1999-04-22
GEP20012578B (en) 2001-11-26
BG64506B1 (bg) 2005-05-31
BG103415A (en) 2000-07-31
TR199900874T2 (xx) 1999-07-21
PL332947A1 (en) 1999-10-25
US6008243A (en) 1999-12-28
AP9901536A0 (en) 1999-06-30
NZ334886A (en) 2000-11-24
SK48499A3 (en) 2000-04-10
CZ132199A3 (cs) 1999-09-15
EA199900366A1 (ru) 1999-10-28
EA003127B1 (ru) 2003-02-27
IL128914A0 (en) 2000-02-17
CN1233237A (zh) 1999-10-27
AU735194B2 (en) 2001-07-05
IS5000A (is) 1999-03-12
AP1360A (en) 2005-01-05
TR200402157T2 (tr) 2005-02-21

Similar Documents

Publication Publication Date Title
YU20199A (sh) Heterociklični sukcinimidi i njihova primena kao metaloproteinaznih inhibitora
GR3034197T3 (en) Inhibitors of nitric oxide biosynthesis.
EA199900591A1 (ru) АЗОТСОДЕРЖАЩИЕ ГЕТЕРОАРОМАТИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха
PL341044A1 (en) Derivatives of orthoantranilic amide as anticoagulants
ID18143A (id) Penghambat metaloprotease amina siklik tersubstitusi
DE69420564D1 (de) Immunsuppressive und antiallergische verbindungen; z.b. n-(3-oxohexanoyl)-homoserinlacton
CA1273019C (en) ENKEPHALINASE INHIBITORS
NZ513164A (en) Substituted porphyrins
EP0202577A3 (en) N(acyldipeptidyl)-aminoglycols
YU57603A (sh) Inhibitori fosfodiesteraze 4
GB9715030D0 (en) Metalloproteinase inhibitors
DE69808099D1 (de) Substituierte 6-alkylphenanthridine
TW372972B (en) Antiretroviral acyl compounds
WO2001009093A8 (en) Benzenamine derivatives as anti-coagulants
DE69728164D1 (de) Peptidomimetische inhibitoren von der protease des menschlichen cytomegalovirus
ES2128031T3 (es) Forma cristalina y polimorfica de (s,s,s)-n-(1-(2-carboxi-3-(n2-mesilisilamino)propil)-1-ciclopentilcarbonil)tirosina.
BG103520A (en) The use of aminothiazoles as microbicides
ES2173634T3 (es) Compuestos heterociclicos que presentan actividad inhibidora de mmp y tnf.
MX9704968A (es) Inhibidores que contienen acido hidroxamico de metaloproteasas de matriz.
ES2099621T3 (es) Procedimiento para producir un derivado de imidazol.